Dr Reddy’s delivered strong revenue growth of 14% YoY. It showed strong growth across all geographies except US where it grew moderately at 8% YoY.
Dr Reddy’s offers several greenshoots like
• 8-10 launches in 2HFY20 will ensure no revenue pressure
• Domestic market outperformance expected to continue with 12-13% growth in next 2 years
• Divestment of non-core assets will help pare debt
The launch of gPlavix in China in late-FY20 could contribute meaningfully in FY21.
The renewed strategy in the US, the enhanced focus on branded generics in emerging markets and the cost-control initiatives are promising steps that bolster the company's earnings prospects.
Disclaimer: The above report is compiled from information available on public platforms. inChat team advises users to check with certified experts before taking any investment decisions.
Found this insight useful?
Please share with your friends and family as well. You can also subscribe to one of our channels listed at the bottom of this page.